Premium
Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMV‐infected perforin‐deficient mice
Author(s) -
Rothman Jennifer A.,
Das Rupali,
Teachey David T.,
Paessler Michele E.,
Nichols Kim E.
Publication year - 2011
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.23226
Subject(s) - hemophagocytic lymphohistiocytosis , hemophagocytosis , lymphocytic choriomeningitis , medicine , perforin , sirolimus , immunology , proinflammatory cytokine , immune system , cd8 , bone marrow , inflammation , pancytopenia , disease
Hemophagocytic lymphohistiocytosis (HLH) is an immunodysregulatory disorder for which more effective treatments are needed. The macrolide rapamycin has immunosuppressive properties, making it an attractive candidate for controlling the aberrant T cell activation that occurs in HLH. To investigate its therapeutic potential, we used rapamycin to treat Lymphocytic Choriomeningitis Virus (LCMV)‐infected perforin‐deficient ( Prf1 −/− ) mice according to a well‐established model of HLH. At the regimens tested, rapamycin did not improve weight loss, splenomegaly, hemophagocytosis, cytopenias, or proinflammatory cytokine production in LCMV‐infected Prf1 −/− animals. Thus, single agent rapamycin appears ineffective in treating the clinical and laboratory manifestations of LCMV‐induced HLH. Pediatr Blood Cancer 2011; 57: 1239–1243. © 2011 Wiley Periodicals, Inc.